Table 2.
Most frequently prescribed ASM/RM during the 12-month baseline period and the first 12 months of the follow-up period
| Observed agents | All SE patients (2782 patients) | SE patients with an epilepsy diagnosis at baseline (1585 patients) | ||
|---|---|---|---|---|
| Baseline period | 12 months of follow-up | Baseline period | 12 months of follow-up | |
| ASM | ||||
| Levetiracetam | 704 (25.31%) | 1318 (47.38%) | 689 (43.47%) | 896 (56.53%) |
| Valproic acid | 363 (13.05%) | 645 (23.18%) | 353 (22.27%) | 486 (30.66%) |
| Lamotrigine | 224 (8.05%) | 311 (11.18%) | 219 (13.82%) | 271 (17.10%) |
| Pregabalin | 136 (4.89%) | 93 (3.34%) | 71 (4.48%) | 51 (3.22%) |
| Carbamazepine | 129 (4.64%) | 99 (3.56%) | 124 (7.82%) | 87 (5.49%) |
| Gabapentin | 115 (4.13%) | 72 (2.59%) | 66 (4.16%) | 49 (3.09%) |
| Lacosamide | 112 (4.03%) | 363 (13.05%) | 112 (7.07%) | 286 (18.04%) |
| Oxcarbazepine | 74 (2.66%) | 94 (3.38%) | 72 (4.54%) | 79 (4.98%) |
| Zonisamide | 54 (1.94%) | 107 (3.85%) | 54 (3.41%) | 88 (5.55%) |
| Topiramate | 50 (1.80%) | 69 (2.48%) | 48 (3.03%) | 57 (3.60%) |
| Primidon | 39 (1.40%) | 31 (1.11%) | 37 (2.33%) | 29 (1.83%) |
| Other ASMa (<1%) | 128 (4.60%) | 235 (8.45%) | 125 (7.89%) | 194 (12.24%) |
| No ASM | 1456 (52.34%) | 862 (30.98%) | 409 (25.80%) | 253 (15.96%) |
| RM | ||||
| Lorazepam | 156 (5.61%) | 278 (9.99%) | 109 (6.88%) | 194 (12.24%) |
| Diazepam | 145 (5.21%) | 283 (10.17%) | 128 (8.08%) | 204 (12.87%) |
| Midazolam | 51 (1.83%) | 124 (4.46%) | 48 (3.03%) | 83 (5.24%) |
| Clobazam | 41 (1.47%) | 94 (3.38%) | 41 (2.59%) | 85 (5.36%) |
| Clonazepam | 40 (1.44%) | 49 (1.76%) | 36 (2.27%) | 40 (2.52%) |
| Other RMb (<1%) | 10 (0.36%) | 7 (0.25%) | 6 (0.38%) | 5 (0.32%) |
| No RM | 2409 (86.59%) | 2116 (76.06%) | 1286 (80.95%) | 1102 (69.53%) |
a
Other ASM with <1% in at least one of the reported periods: eslicarbazepine, phenytoin, perampanel, brivaracetam, phenobarbital, sultiame, ethosuximide, vigabatrin, stiripentol, rufinamide, acetazolamide and potassium bromide. bOther RM with <1% in at least one of the reported periods: alprazolam and chloral hydrate.